S

Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399

Watchlist Manager
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Watchlist
Price: 10.8 CNY -5.1% Market Closed
Market Cap: 13.5B CNY
Have any thoughts about
Shenzhen Hepalink Pharmaceutical Group Co Ltd?
Write Note

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Net Issuance of Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
S
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Net Issuance of Debt
-ÂĄ1.6B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Net Issuance of Debt
-ÂĄ19m
CAGR 3-Years
-36%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Net Issuance of Debt
ÂĄ163.2m
CAGR 3-Years
176%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Net Issuance of Debt
-ÂĄ16.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Net Issuance of Debt
ÂĄ894.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Net Issuance of Debt
ÂĄ208m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Glance View

Market Cap
13.5B CNY
Industry
Pharmaceuticals

Shenzhen Hepalink Pharmaceutical Group Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Shenzhen, Guangdong and currently employs 2,046 full-time employees. The company went IPO on 2010-05-06. Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based pharmaceutical company focused on the field of heparin sodium preparations and raw materials, macromolecular drugs contract development manufacturing organization (CDMO) and innovative drug development. The Company’s main products and services include enoxaparin sodium preparations and heparin sodium bulk medicines, enoxaparin sodium bulk medicines, and CDMO services for macromolecular drugs. The firm distributes its products within the domestic market and to overseas markets, including Turkey, Brazil, the United States and others.

Intrinsic Value
12.99 CNY
Undervaluation 17%
Intrinsic Value
Price
S

See Also

What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's Net Issuance of Debt?
Net Issuance of Debt
-1.6B CNY

Based on the financial report for Sep 30, 2024, Shenzhen Hepalink Pharmaceutical Group Co Ltd's Net Issuance of Debt amounts to -1.6B CNY.

What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 1Y
-40%

Over the last year, the Net Issuance of Debt growth was -40%.

Back to Top